MRM
ATRC icon

Michael R. Murphy’s AtriCure ATRC Stock Holding History

Michael R. Murphy’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-786,950
Closed -$7.48M – 24
2013
Q2 		$7.48M Buy
+786,950
New +$6.86M 3.42% 11

Other funds holding ATRC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Michael R. Murphy's ATRC Position: Q3 2013 in Review

Michael R. Murphy sold out of AtriCure (ATRC) in Q3 2013, closing a stake of 786,950 shares — an estimated $7.48M sold.

Michael R. Murphy first reported a position in ATRC in Q2 2013 and held it in 1 quarter. The position peaked at $7.48M in Q2 2013. 79 funds tracked by Wall St. Rank hold ATRC as of Q3 2013.

  • Michael R. Murphy reported no remaining AtriCure position as of Q3 2013 after selling out during the quarter.
  • Michael R. Murphy sold 786,950 AtriCure shares in Q3 2013, an estimated $7.48M.
  • Michael R. Murphy first reported a position in AtriCure in Q2 2013 and held it in 1 quarter.
  • Michael R. Murphy's AtriCure position peaked at $7.48M in Q2 2013.
  • 79 funds tracked by Wall St. Rank held AtriCure as of Q3 2013.

Based on Michael R. Murphy's 13F filing for Q3 2013, filed 13 Nov 2013.